Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety

K L Hyrich; A J Silman; K D Watson; D P M Symmons

doi:10.1136/ard.2004.024737

Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety

Ann Rheum Dis. 2004 Dec;63(12):1538-43. doi: 10.1136/ard.2004.024737. Epub 2004 Jul 8.

Authors

K L Hyrich¹, A J Silman, K D Watson, D P M Symmons

Affiliation

¹ ARC Epidemiology Unit, University of Manchester, Oxford Road, Manchester M13 9PT, UK.

Abstract

Anti-TNFalpha therapy may have associated risks of serious infection, congestive heart failure, malignancy, and multiple sclerosis. The magnitude of these risks is difficult to assess. This article reviews publications on the current knowledge about the safety of these agents.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / adverse effects*
Antirheumatic Agents / adverse effects*
Arthritis, Rheumatoid / drug therapy*
Autoimmune Diseases / chemically induced
Etanercept
Heart Failure / chemically induced
Humans
Immunoglobulin G / adverse effects*
Infliximab
Opportunistic Infections / chemically induced
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha / antagonists & inhibitors*

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Immunoglobulin G
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
Infliximab
Etanercept